UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2023

Chimerix, Inc.

(Exact name of registrant as specified in its charter)

001-35867

(Commission File Number)

33-0903395

(IRS Employer Identification No.)

27713

(Zip Code)

Delaware (State or other jurisdiction of incorporation)

2505 Meridian Parkway, Suite 100 Durham, NC

(Address of principal executive offices)

(919) 806-1074 (Registrant's telephone number, including area code)

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

П Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	CMRX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company \Box

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 🗆

Item 2.02 Results of Operations and Financial Condition.

On August 3, 2023, Chimerix, Inc, (the "Company") announced our financial results for the six months ended June 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On August 3, 2023, the Company also made available an updated corporate presentation (the "Presentation") that the Company intends to use, in whole or in part, in meetings with investors, analysts and others. The Presentation can be accessed through the "Investors" section of the Company's website. A copy of the Presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in Item 2.02, Item 7.01 and the attached Exhibit 99.1 and 99.2 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02, Item 7.01 and the attached Exhibit 99.1 and 99.2 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits

Exhibit No.	Description
99.1	Press Release of Chimerix, Inc. dated August 3, 2023.
99.2	Chimerix, Inc. Corporate Presentation, dated August 3, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Chimerix, Inc.

Date: August 3, 2023

By: Name: Title:

/s/ Michael T. Andriole Michael T. Andriole President and Chief Executive Officer



Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

- Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 -

- ONC206 Dose Escalation Completion Expected in First Half 2024 -

- Capital Available to Fund Operations is \$233 Million as of June 30, 2023 -

– Conference Call at 8:30 a.m. ET Today –

DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an operational update.

"I am thrilled to begin leading the organization during such a pivotal time in Chimerix's history and in the field of neuro-oncology, where several genetically defined programs have advanced the field recently. During the second quarter, our team has been laser focused on site activation and enrollment of the Phase 3 ACTION study which now includes 77 sites enrolling patients across 11 countries and an enrollment rate that remains on track for the first interim overall survival analysis in early 2025. We are incredibly grateful to the neuro-oncology community which is eagerly supporting the ACTION study in order to advance the treatment for patients with this cancer. H3 K27M-mutant glioma is estimated to occur in 5,000 people annually in the major global markets," said Mike Andriole, Chief Executive Officer of Chimerix.

"Furthermore, dose escalation for our second-generation compound, ONC206, continues and completion is expected in the first half of 2024. There have been no dose limiting toxicities identified during dose escalation thus far and we are now exploring a more intense dose and schedule with the goal of identifying additional signals of activity," added Mr. Andriole.

ONC201 for Treatment of H3 K27M-Mutant Diffuse Glioma

The Phase 3 ACTION trial is currently enrolling patients at 77 sites in 11 countries and remains on track to report interim data in early 2025.

The ACTION trial is enrolling patients shortly after they have completed standard of care front-line radiation therapy. The study is designed to enroll 450 patients randomized 1:1:1 to receive ONC201 at one of two dosing frequencies or placebo. Participants will be randomized to receive 625mg of ONC201 once per week (the Phase 2 dosing regimen), 625mg twice per week on two consecutive days or placebo. The dose will be scaled by body weight for patients <52.5kg. Overall survival (OS) will be assessed for efficacy at three alpha-allocated timepoints: two interim assessments by the Independent Data Monitoring Committee (IDMC) at 164 events and 246 events, respectively, and a final assessment at 327 events. The final progression-free survival (PFS) analysis will be performed after 286 events, with progression assessed using RANO HGG criteria by blinded independent central review (BICR). Secondary endpoints include corticosteroid response, performance status response, change from baseline in quality of life (QoL) assessments and change from baseline in neurologic function as assessed by the Neurologic Assessment in Neuro-Oncology (NANO) scale.

ONC206

ONC206 is a second generation DRD2 antagonist and ClpP agonist that has demonstrated monotherapy anti-cancer activity in pre-clinical models. Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC). In March 2023, the Company reported an investigator-assessed response in a patient with recurrent glioblastoma without the H3K27M-mutation. The patient has continued to respond and remains on treatment, receiving increasing doses as part of the dose escalation. To date, ONC206 is generally well tolerated with a similar safety profile in adults and pediatrics. No dose limiting toxicities have been identified to date. The dose escalation trials are transitioning to intensify dosing from a once weekly dosing to a more frequent dose schedule to increase the duration of therapeutic exposure.

Second Quarter 2023 Financial Results

Chimerix reported a net loss of \$18.6 million, or \$0.21 per basic and diluted share, for the second quarter of 2023. During the same period in 2022, Chimerix recorded a net loss of \$23.5 million, or \$0.27 per basic and diluted share.

Research and development expenses decreased to \$16.9 million for the second quarter of 2023, compared to \$18.0 million for the same period in 2022.

General and administrative expenses decreased to \$4.4 million for the second guarter of 2023, compared to \$5.8 million for the same period in 2022.

Chimerix's balance sheet at June 30, 2023 included \$233.0 million of capital available to fund operations, approximately 88.6 million outstanding shares of common stock and no outstanding debt.

Conference Call and Webcast

Chimerix will host a conference call and live audio webcast to discuss second quarter 2023 financial results and provide a business update today at 8:30 a.m. ET. To access the live conference call, please dial 646-307-1963 (domestic) or 800-715-9871 (international) at least five minutes prior to the start time and refer to conference ID 8015897. A live audio webcast of the call will also be available on the Investors section of Chimerix's website, <u>www.chimerix.com</u>. An archived webcast will be available on the Chimerix website approximately two hours after the event.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the probability of success of the Phase 3 ACTION study, the potential filing and approval of an NDA for ONC201 and subsequent commercial opportunity, the implications of the monotherapy radiographic partial response observed during ONC206 dose escalation, the ability to reproduce clinical and pre-clinical findings, and projections regarding funding and timing of future data readouts. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to the timing, completion and outcome of the Phase 3 ACTION study of ONC201; risks associated with repeating positive results obtained in prior preclinical or clinical studies

in future studies; risks related to the clinical development of ONC206; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACTS:

Michelle LaSpaluto 919-972-7115 ir@chimerix.com

Will O'Connor Stern Investor Relations 212-362-1200 <u>Will@sternir.com</u>

CHIMERIX, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited)

		June 30, 2023	Dece	mber 31, 2022
ASSETS				
Current assets:				
Cash and cash equivalents	\$	20,099	\$	25,842
Short-term investments, available-for-sale		185,657		191,492
Accounts receivable		26		1,040
Prepaid expenses and other current assets		5,735		9,764
Total current assets		211,517		228,138
Long-term investments		27,258		48,626
Property and equipment, net of accumulated depreciation		256		227
Operating lease right-of-use assets		1,728		1,964
Other long-term assets		326		386
Total assets	\$	241,085	\$	279,341
LIABILITIES AND STOCKHOLDERS' EQUITY	-			
Current liabilities:				
Accounts payable	\$	1,823	\$	3,034
Accrued liabilities		13,518		17,381
Total current liabilities		15,341		20,415
Line of credit commitment fee		125		250
Lease-related obligations		1,507		1,819
Total liabilities		16,973		22,484
Stockholders' equity:				
Preferred stock, \$0.001 par value, 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding as of June 30, 2023 and December 31, 2022		_		_
Common stock, \$0.001 par value, 200,000,000 shares authorized at June 30, 2023 and December 31, 2022; 88,583,567 and 88,054,127 shares issued and outstanding as 0 June 30, 2023 and December 31, 2022, respectively	of	89		88
Additional paid-in capital		978,213		970,535
Accumulated other comprehensive loss, net		(813)		(337)
Accumulated deficit		(753,377)		(713,429)
Total stockholders' equity		224,112		256,857
Total liabilities and stockholders' equity	\$	241,085	\$	279,341

CHIMERIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited)

	Three Months Ended June 30,			Six Months Ended June 30,		
	 2023		2022	 2023		2022
Revenues:						
Contract and grant revenue	\$ 26	\$	_	\$ 260	\$	_
Licensing revenue	—		440	49		455
Total revenues	 26		440	 309		455
Cost of goods sold	—		—	—		114
Gross profit	26		440	309		341
Operating expenses:						
Research and development	16,926		18,047	35,748		37,087
General and administrative	 4,448		5,840	 10,127		11,472
Total operating expenses	21,374		23,887	45,875		48,559
Loss from operations	(21,348)		(23,447)	(45,566)		(48,218)
Other income (loss):						
Interest income and other, net	 2,772		(21)	 5,618		(17)
Net loss	(18,576)		(23,468)	(39,948)		(48,235)
Other comprehensive loss:						
Unrealized (loss) gain on debt investments, net	 (582)		5	 (476)		(47)
Comprehensive loss	\$ (19,158)	\$	(23,463)	\$ (40,424)	\$	(48,282)
Per share information:	 					
Net loss, basic and diluted	\$ (0.21)	\$	(0.27)	\$ (0.45)	\$	(0.55)
Weighted-average shares outstanding, basic and diluted	88,583,567		87,436,180	88,439,894		87,263,452

Chimerix Corporate Presentation

August 3, 2023






Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, the probability of success of the Phase 3 ACTION study, the potential filing and approval of an NDA for ONC201 and subsequent commercial opportunity, the implications of the monotherapy radiographic partial response observed during ONC206 dose escalation; the ability to reproduce clinical and pre-clinical findings, and projections regarding funding and timing of future data readouts. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to the timing, completion and outcome of the Phase 3 ACTION study of ONC201; risks associated with repeating positive results obtained in prior preclinical or clinical studies in future studies; risks related to the clinical development of ONC206; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

5 2



Deep pipeline across all development stages

Program	Preclinical	Phase 1	Phase 2	Registrational	FDA review	Collaborators
ONC201 (dordaviprone)						
H3 K27M-mutant glioma (orphan	drug, ¹ fast track ² and ra	re pediatric disea	se designations ³)			
IITs- signal finding, multiple onco	logy indications/combina	tions				
ONC206						National Institutes of Health
CNS ⁴ tumors						
ONC212						MD Anderson Cancer Center
IND-enabling studies						BROWN
CMX521						
SARS-CoV-2						🛟 READDI 🕯
TEMBEXA® transacted with En	nergent BioSolutions					
Smallpox (orphan drug designation)				APPRO	VED June 4, 2021	BARDA
1 Malignant glioma Adult neurrent H3 K27M-mutant high-gn 3 H3 K27M-mutant glioma 4 Centra Nervous System 5 Rapidly Emerging Antiviral Drug Develop						EMERGENT








H3 K27M-mutant diffuse glioma: high unmet need

- H3 K27M mutation is predominantly • found among diffuse midline gliomas (DMGs) in young adults and children
- Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible
- DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal
- Studies consistently indicate longer • OS of ONC201-treated glioma patients relative to diverse external controls

Frontline H3 K27M DMG External analysis reported at







Company Sponsored Studies

	Natural Disease History: Recurrent H3 K27M and/or DMG ³ (n=43)	ONC201 Phase 2: Recurrent H3 K27M DMG (n=50)
Median OS,mo (95% CI)	5.1 (3.9-7.7)	13.7 (8-20.3)
OS @ 12mo (95% CI)	23.6% (11.7-37.9)	57% (41-70)
OS @ 24mo (95% CI)	11.1% (3.3-24.2)	35% (21-49)

8

¹ Lulla RR et al. Sci Adv. 2016;2(3):e1501354
² Sunjong JI, B.S. et al, "Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma", Society of Neuro-oncology 2022
³ The median OS was 5.1 months for the subset of patients with H3 K27M-mutant diffuse glioma excluding DIPG, CSF dissemination, spinal or leptomeningeal disease (N=12), OS at 12 mos was 25.0%, OS at 24 mos was 16.7% 6

Phase 2 efficacy for ONC201 in recurrent H3 K27M DMG

- ONC201 monotherapy exhibited durable, clinically meaningful efficacy in recurrent H3 K27M-mutant DMG
 - Overall Response Rate (ORR) of 30% (95% CI: 18 45%) by RANO HGG and/or LGG dual reader BICR
 - RANO-HGG criteria assessed by dual reader BICR
 - ORR 20% (95% CI: 10 34%)
 - Median Duration of Response (DOR) 11.2 months (95% CI: 3.8 not reached)
 - Median time to response 8.3 months (range 1.9 15.9)
 - Disease control rate 40% (95% CI: 26 55%)
 - PFS at 6 months 35% (95% CI: 21 49%); PFS at 12 months 30% (95% CI: 17 44%)
 - RANO-LGG criteria assessed by dual reader BICR
 - ORR 26% (95% CI: 15 40%)
 - Overall survival
 - 12 months: 57% (95% CI:41 70%)
 - 24 months: 35% (95% CI: 21 49%)
- · Improvements observed in performance status and reduction in corticosteroid use
- All SAEs considered not related to ONC201 by sponsor

8 7

FDA-aligned criteria for Phase 2 efficacy analysis to isolate ONC201 single agent activity

Objective


• To evaluate monotherapy efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma

Eligibility


- Age ≥2yo and received ONC201 under studies ONC006, ONC013, ONC014, ONC016, or ONC018
- Diffuse glioma with a known H3 K27M mutation and involvement of a midline structure of the brain
- Progressive and measurable disease on contrast-enhanced brain MRI by RANO-High Grade Glioma (HGG) criteria
- Prior therapy with at least radiation
- Washouts prior to first ONC201 dose:
 - Radiation: 90 days
 - Temozolomide: 23 days / Antibodies (e.g., bevacizumab): 42 days / Other anticancer therapies: 28 days
- Baseline Performance Status ≥60
- Corticosteroids stable or decreasing for at least 3 days prior to baseline scan
- Excluded: DIPG, primary spinal tumors, atypical and non-astrocytic hist., leptomeningeal spread, CSF dissemination


8 8

ONC201 waterfall plot - 30% RANO HGG / LGG response




- Strict selection criteria to ensure responses attributable to single agent treatment
- Responses require both imaging and clinical criteria
- Dual reader blinded independent central review (BICR)
- Growing consensus that assessment of enhancing and non-enhancing disease (RANO-HGG and RANO-LGG criteria) is needed for diffuse midline glioma





Clinically meaningful and durable RANO-HGG responses



ONC201 Phase 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant Diffuse Midline Glioma

ONC201 safety

Healthy Adult Dose Escalation Study¹ Incidence of ONC201-Related Adverse Events (AE)

	125 mg N=33	375 mg N=15	625 mg N=45
Any treatment-related AE	36.0%	20.0%	53.0%
Grade 1	36.0%	20.0%	53.0%
Grade 2	0	0	0
Grade 3-5	0	0	0

- · In addition to healthy adult dose escalation study above, clinical pharmacology studies included: food-effect, safety pharmacology, special populations, and drug-drug interaction studies
- · Treatment-related AEs were generally Grade 1 and transient across the clinical pharmacology program.
- The most commonly reported treatment-related events were mild dizziness, headache and nausea. •



 1.
 Based on available data as 25Apr/2023 for ONC201-101

 2.
 Reported in ONC201 Investigator Brochure

Treatment-related Adverse Events in ≥ 3% Glioma Patients

Treatment-related Adverse Events,	Related	TEAEs	
Integrated Safety Data Set, (N=211 glioma patients) ²	All grades	Grade > 3	
Any Treatment-related AE	55.5%	11.8%	
Fatigue	21.8%	2.8%	
Nausea	20.4%	0	
Vomiting	14.2%	0.5%	
Headache	8.5%	0.5%	
Lymphocyte count decreased	6.6%	0.5%	
Decreased appetite	5.7%	0	
White blood cell count decreased	4.7%	0.5%	
ALT increased	4.3%	0.5%	
Hypophosphataemia	4.3%	0	
Neutrophil count decreased	3.8%	0.5%	
Anaemia	3.3%	0	
Diarrhea	3.3%	0	

RANO responses correspond with survival & clinical benefit

ONC201 Ph 2 Efficacy Analysis by BICR in Recurrent H3 K27M-mutant DMG

			All patients	RANO HGG Responders	RANO HGG and/or LGG Responders
٠	No patients who experienced a RANO- HGG response had a reported death at 24 months ²	Ν	50	10	15
•	at 24 months ² RANO response strongly associated with reduction in steroid use and improvement in performance status	PFS at 12 months (number of patients censored)	30% ¹	90% (0)	67% (2)
		OS at 24 months (number of patients censored) ²	35% ¹	80% (2)	53% (5)
		Corticosteroids response ³ (number of patients evaluable)	47% (15)	100% (4)	100% (5)
		Performance status response ⁴ (number of patients evaluable)	21% (34)	60% (5)	67% (9)

Kaplan-Meler median Progression-Free Survival or Overall Survival
 Censored patients include those who are lost to follow-up or have withdrawn prior to the time point, as well as those who have not yet reached the time point. These patients are counted in the denominator but not counted as survivors (i.e., imputed as failure)
 Corticosteroid response: 50% reduction in average daily corticosteroid dose compared to baseline were evaluable.
 Performance status response: increase in KPS/LPS compared to baseline with stable or reduced corticosteroid use. Must be confirmed at next analysis timepoint. Baseline KPS/LPS set0 were evaluable.

Strong rationale for phase 3 success relative to recent GBM trials

Experimental Agent	Ph2 Design	Biomarker	Response criteria	Confounded by anti-angiogenic pseudo response	ORR	Duration of response	6 month PFS	Approved?
ONC201– Ph2 rDMG	Single agent	H3 K27M	RANO BICR	No	20-30%	11.2	35%	To be determined
	Single agent	-	Levin	No	5%	?	21%	Yes (OS)
AVASTIN bevacizumab	Various	-	Various	Yes	20-70%	4-6	18- <mark>50%</mark>	Yes (AA per ORR, PFS)
Cediranib	Single agent	-	MacDonald	Yes	27%	?	26%	No
Rindopepimut	Combo + Avastin	EGFRv3	RANO	Yes	30%	7.8	28%	No
Depatuxizumab mafodotin	Single agent	-	RANO	No	7%	6.7	29%	No
Enzastaurin	Combo + Avastin	-	RANO	Yes	22%	?	21%	No

K 15 Positive Neutral Negative Characteristics WKA Yung, et al, British Journal Cancer, Aug 8, 2000; Teri Kreisl, et all, Journal Clinical Oncology, 2009; Feb 10;27(5);740-5; Tracy Batchelor, et. all, Journal of Clinical Oncology, vol28, issue 17, Jun 10, 2010; David Reardon, et al, Clin Cancer Research Apr 2020; 26(7):1586-1594; Martin van den Bent, et al, Cancer Cherro & Pharma, 26 Oct 2017 80, 1209-1217; Yazmin Odia, et al, Journal Neuro-Oncology 127, 127-125 (2016)




ONC201 Phase 3 ACTION

Study Summary


Pivotal Phase 3 ACTION trial design

Now enrolling, a randomized, double-blind, placebo-controlled, multicenter international study in 450 newly diagnosed diffuse glioma patients whose tumor harbors an H3 K27M-mutation.



17 1. Excludes DIPG and spinal tumors

Multiple unique aspects to ONC201 data support translation to phase 3 success



\$ 18

- Responses not confounded by combination treatments
- Responses were gradual, • durable, and multi-focal
- . Responses observed via most stringent criteria in blinded assessment

Consistency across 1. multiple endpoints

- Responses highly associated with other forms of clinical benefit
- PFS and OS favorable to . historical benchmarks
- · Multiple separate analyses suggest longer survival of patients who received ONC201



Enhanced activity not required, but likely

- Earlier setting associated with higher response rate (performance status, tumor volume)
- Addition of higher-dose study • arm
- Biomarker selection supports patient homogeneity


Design provides multiple paths for success

Interim data expected in early 2025 and final data in 2026

First OS ⁽¹⁾ Interim	PFS by RANO HGG ⁽²⁾	Second OS Interim	Final OS
 ~164 events 	 ~286 events 	 ~246 events 	 ~327 events
 Success at HR⁽³⁾=0.52 	 Success at HR=0.68 	 Success at HR=0.64 	 Success at HR=0.7
1. Overall Survival (OS)			

Potentia	l to iı	ncrea	se ONC201
efficacy	with	dose	schedule

- Once per week ONC201 dosing effective as monotherapy in Phase 2 studies
- Twice per week dosing on two consecutive days expected to increase duration of therapeutic exposure
 - Increased exposure time can increase glioma sensitivity to ONC201 in vitro
 - Generally well tolerated in Phase 1 without dose limiting toxicity or AEs leading to dose modification
- Phase 3 ACTION study will evaluate once per week and twice per week dosing schedules at 625mg (or body weight equivalent)



20

ONC201 Market Opportunity Assessment



Approximately 21,000 gliomas reported in the U.S. each year, affecting all locations in the brain¹

- ~40% of 4,000+ <u>midline gliomas</u> are expected to harbor the H3 K27M mutation²
- ~2% of 17,000+ <u>non-midline gliomas</u> are expected to harbor the H3 K27M mutation²
- Each year it is estimated that ~2,000 patients -are affected by H3 K27M-mutant glioma in the U.S;
 ~5,000 patients in the top seven global markets

Estimated # of U.S. H3 K27M+ Patients by Tumor Location (rate of positivity)² Non-midline ~350 patients (~2%) Thalamic 220 patients (52%) Ventricle 250 patients (71%) Pineal 40 patients (20%) Pons Cerebellum 240 patients (22%) 290 patients (75%) Spinal cord Brainstem 370 patients (49%) (excluding pons) 270 patients (50%)


La Bare method: 301:2015/1630 Start S, et al. Active Mercandol 2016;4(1):31: Abare Mark A, et al. All Mercandol 2017;8(1):21: Active Mark A, et al

H3 K27M-mutant glioma: rapid ramp to peak revenue expected


- No approved therapies for H3 K27M mutant glioma, ONC201 is the leading program targeting this mutation globally
- Potential market opportunity ~\$750 million
- Approximately 5,000 patients in top seven markets
- Ultra-orphan indication drug pricing
- H3 K27M mutations most often in children / young adults (little exposure to Medicare)
- Low barriers to adoption
 - No effective alternative therapies
 - High unaided awareness among neuro-oncologists
 - Mutation routinely identified by existing diagnostics
 - Longer-term, potentially combinable with other glioma therapies
- Patent protection for lead indication into 2037 potential U.S. patent term extension (up to five years)

23

Regulatory designations



ONC201 interim efficacy results in dopamine-secreting tumors outside the brain




- Single agent responses in Ph 2 neuroendocrine trial of ONC201 observed in subset (paraganglioma)
- Paraganglioma are adrenal-related tumors with elevated DRD2 expression
- Five patients have been treated > 1 year
- Fewer short-term and potential long-term toxicities than other paraganglioma therapies



ONC201 Mechanism of Action

ONC201 directly engages DRD2 and ClpP


ONC201 upregulates integrated stress response, inactivates Akt/ERK, and selectively induces tumor cell death




H3 K27M glioma primed for ONC201 sensitivity


DRD2 pathway inhibited by ONC201 is enriched in H3 K27M glioma

H3 K27M is hypersensitive to ONC201





H3 K27M glioma often located in dopamine-rich environment




Ex vivo high grade glioma growth sensitivity to ONC201 by H3 status



Chi et al., Society of Neuro-Oncology, 2017; Piccardo et al., Eur J. Nucl Med Mol Imaging, 2019








ONC206


ONC206: oral brain penetrant DRD2 antagonist + ClpP agonist

- Second generation imipridone designed to expand to new indications
- Efficacy in cell culture, xenograft and transgenic central nervous system (CNS) and other tumor models
- Oral dose escalation trials ongoing in CNS cancers
- Monotherapy response reported by investigator in early dose escalation cohort for a patient in recurrent non-H3 K27M GBM
 - Dordaviprone responses amongst CNS tumors exclusively in H3K27M gliomas
 - Dose level 2 (100mg), once weekly dosing



31 1. PDB 6CM4 2. PDB 6DL7

ONC206 monotherapy active in models of CNS and other cancers



ONC206 dose escalation: pediatric and adult CNS tumors


- Monotherapy dose escalation trials enrolling in parallel for adult and pediatric CNS tumors
- Response reported by investigator from early cohort (100mg QW) without H3 K27M mutation
 - 18-year-old patient with recurrent temporal lobe glioblastoma
 - Regression on MRI & metabolic reduction via PET imaging, continuing on therapy over 15 months
- Once weekly dose escalation is expected to intensify to three consecutive days per week



Dose intensification expected to enhance duration of therapeutic exposure

- Consecutive day dosing may increase therapeutic response
 - In vitro data demonstrates enhanced efficacy with 72 hour sustained exposure
 - Toxicology data enables safe escalation to more prolonged exposures
- Phase 1 trial data suggest a therapeutic and safe exposure possible with twice daily, three times weekly dosing


34 1. Internal modeling



ONC206 dose escalation increasing to more frequent dosing

Dose escalation on track for completion in 1H24

- No DLTs observed with weekly dosing
 - Similar safety profile in adults and pediatrics
 - Majority of treatment-related AEs are mild to moderate
 - Most common treatmentrelated events are fatigue, lymphocyte count decreased, and vomiting
 - No dose related toxicity with dose escalation – dose escalation continuing



In vitro data indicates correlation between exposure time and tumor cell viability; more frequent dosing schedule designed to increase duration of target exposure

 35
 1.
 Dose level 6 was conducted in adults

 2.
 Pediatric dose scaled by body weight

✓ Dose level complete

~30,000 new cases of GBM annually in the top 7 markets; >\$2Bn market opportunity

- GBM is a rapidly progressive disease with low survival rates, few drug approvals last 25 years:
 - Temozolomide (TMZ) approved 1999
 - Bevacizumab approved 2009
- Existing therapies rarely offer durable effect



- Chimerix retains global operational rights to ONC206²
- Worldwide market opportunity exceeds \$2Bn
 - TMZ revenue peaked at approximately \$1.4 billion in 2009, prior to going generic
 o Inflation adjusted peak: > \$2.5Bn
 - New GBM therapy: 50% penetration at average price of contemporary oncology drug approvals exceeds \$2Bn

36 1 wjso.biomedcentral.com/articles/10.1188/1477-7819-10-220 ² Royatties and milestones are owed to legacy Oncoceutics shareholders by virtue of the 2021 merger agreement



Preclinical

Development


ONC212 and CMX521

ONC212: GPR132 + ClpP Agonist

- Distinct molecular target (GPR132) and efficacy profile relative to ONC201/ONC206
- Efficacy in preclinical models of advanced cancers .
- GLP-tox studies complete, potential to advance to IND •
- Partnerships established for early-stage clinical trials • with Brown University and MD Anderson Cancer Center
- Preclinical studies are ongoing to evaluate additional • oncology indications and predictive biomarkers for ONC212 for clinical development

Pancreatic cancer model shows the potential of ONC2121

Vehicle ONC201 ONC212






CMX-521: anti-SARS-CoV-2 preclinical activity

- Ribonucleoside analog that is a viral polymerase inhibitor
 Inhaled nebulized liquid aerosol formulation; minimal systemic exposure
- Monotherapy efficacy in mouse-adapted SARS-CoV-2-MA10 model across multiple endpoints
 - Lung viral titer
 - Viral RNA parallel viral lung titer (plaque forming unit)
 - Clinical scoring (animal health)
 - Lung pathology
 - Animal weight loss

\$2 million grant to fund prodrug formulations that could enable oral administration with improved lung delivery



39 1. Replicates lung pathology of human infection 4-days post-infection. One day in mouse is 5-7 days in humans (adjusted disease course).

 \bigcirc



Corporate Update

TEMBEXA® deal term summary

Emergent BioSolutions is an experienced biodefense company collaborating with government agencies to protect public health

Terms summary:

- \$238 million received upfront at closing in Q3 2022
- Up to an additional \$124 million in potential BARDA procurement milestones
- 20% royalty on future U.S. gross profit with volumes above 1.7 million courses of therapy
- 15% royalty of all international gross profit
- Up to an additional \$12.5 million in development milestones





Financial strength supports development through key catalysts

